Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,718 Mln
Revenue (TTM)
$234 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5
Industry P/E
--
EV/EBITDA
-3.2
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$--
EPS
$-2.7
Face value
--
Shares outstanding
42,014,200
CFO
$-188.77 Mln
EBITDA
$-244.17 Mln
Net Profit
$-244.61 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
| -25.4 | -5.1 | -14.1 | 33.3 | 46.7 | -- | -- |
|
BSE Sensex*
| 4.2 | -0.9 | 10.5 | 5.9 | 16.6 | 19.4 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
| 171.2 | 38.1 | -34.8 | -45.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tarsus Pharmaceuticals Inc (TARS)
|
41.3 | 1,718.0 | 233.7 | -104.9 | -42.9 | -36.2 | -- | 5.0 |
| 51.6 | 7,919.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.9 | 3.9 | |
| 128.3 | 8,274.7 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.0 | 7,460.2 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 41.8 | 11,341.9 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 301.0 | 8,572.2 | 2,156.6 | 416.4 | 21.2 | 56.5 | 22.8 | 14.4 | |
| 26.0 | 10,314.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 125.0 | 12,371.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.2 | 4.9 | |
| 288.6 | 12,781.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.3 | 1.9 |
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel... therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Read more
Co-Founder, President, CEO & Chairman
Dr. Bobak R. Azamian M.D.
Co-Founder, President, CEO & Chairman
Dr. Bobak R. Azamian M.D.
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tarsus Pharmaceuticals Inc (TARS) stood at $ 587 Mln as on 31-Mar-25
The share price of Tarsus Pharmaceuticals Inc (TARS) is $41.29 (NASDAQ) as of 16-Jun-2025 16:00 EDT. Tarsus Pharmaceuticals Inc (TARS) has given a return of 46.66% in the last 3 years.
Tarsus Pharmaceuticals Inc (TARS) has a market capitalisation of $ 1,718 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Tarsus Pharmaceuticals Inc (TARS) is 5.02 times as on 13-Jun-2025, a 89% premium to its peers’ median range of 2.65 times.
Since, TTM earnings of Tarsus Pharmaceuticals Inc (TARS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tarsus Pharmaceuticals Inc (TARS) and enter the required number of quantities and click on buy to purchase the shares of Tarsus Pharmaceuticals Inc (TARS).
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
The CEO & director of Dr. Bobak R. Azamian M.D.. is Tarsus Pharmaceuticals Inc (TARS), and CFO & Sr. VP is Dr. Bobak R. Azamian M.D..
There is no promoter pledging in Tarsus Pharmaceuticals Inc (TARS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Tarsus Pharmaceuticals Inc (TARS) | Ratios |
|---|---|
|
Return on equity(%)
|
-36.19
|
|
Operating margin(%)
|
-42.91
|
|
Net Margin(%)
|
-44.91
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tarsus Pharmaceuticals Inc (TARS) was $0 Mln.
$0.40
(
